We are developing gene therapies to treat hereditary blood disorders. Our lead project aims at curing Beta-Hemoglobinopathies which are the most common deadly monogenetic disorders worldwide with millions of affected individuals.The Beta-hemoglobinopathies are the most common monogenetic diseases worldwide with approximately 360,000 annual births with a serious form of the disease, and 7% of the world population being carriers. Current treatment options are limited, and no safe curative treatments exist. We are developing a one-time gene therapy that will reduce all disease symptoms in patients.
Location: Switzerland, Zurich, Schlieren
Member count: 1-10
Investors 1
| Date | Name | Website |
| 11.06.2023 | Venture Ki... | venturekic... |